Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

British journal of haematology·2026

Same author

Integrative Traditional East Asian Medicine-Based Adjunctive Therapies for Patients With Prostate Cancer Undergoing Standard Cancer Treatment: Protocol for a Systematic Review and Meta-Analysis of Randomized Controlled Trials.

JMIR research protocols·2026

Same author

Industrial influence on atmospheric VOCs and associated health risks in small residential areas near industrial complexes in Ulsan, South Korea.

Environmental monitoring and assessment·2026

Same author

Response kinetics as a dynamic prognostic marker in patients with multiple myeloma.

Leukemia·2026

Same author

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).

Blood·2026

Same author

Aberrant TIMM8B alternative splicing compromises mitochondrial respiratory chain integrity and redox homeostasis.

Free radical biology & medicine·2026

Search research articles

Related Experiment Video

Updated: Jul 6, 2025

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

4-1BB immunotherapy: advances and hurdles.

Rohit Singh¹, Young-Ho Kim², Sang-Jin Lee¹

¹Immuno-oncology Branch, Division of Rare and Refractory Cancer, National Cancer Center, Goyang, 10408, Republic of Korea.

Experimental & Molecular Medicine

|January 3, 2024

Summary

4-1BB receptor agonists show promise in cancer immunity but cause adverse events like hepatotoxicity. New therapies aim to enhance T-cell modulation while reducing side effects for better immunotherapy.

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Related Experiment Videos

Last Updated: Jul 6, 2025

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Area of Science:

Immunology
Oncology
Pharmacology

Background:

4-1BB is a key T-cell receptor involved in immune responses.
Its role in infection and tumor immunity is well-established.
Clinical use of 4-1BB agonists is limited by severe adverse events, particularly hepatotoxicity.

Purpose of the Study:

To review the role of 4-1BB in T-cell biology.
To explore clinical applications of 4-1BB agonists.
To discuss future directions for 4-1BB-based immunotherapy.

Main Methods:

Literature review of T-cell biology and 4-1BB function.
Analysis of clinical trial data for 4-1BB agonist antibodies.
Examination of preclinical studies on novel 4-1BB therapeutics.

Main Results:

4-1BB plays a critical role in T-cell activation and function.
4-1BB agonist antibodies demonstrate efficacy in preclinical tumor models.
Hepatotoxicity is a significant dose-limiting toxicity in clinical trials.

Conclusions:

Developing safer 4-1BB agonists is crucial for effective cancer immunotherapy.
Next-generation therapies focus on modified effector functions to balance efficacy and safety.
Future prospects include novel antibody formats and recombinant proteins for improved therapeutic windows.